The European regulatory review of SkyePharma Plc’s asthma treatment, Flutiform, will take longer than originally anticipated due to a lack of complete consensus among the member states about the product, SkyePharma announced on 18 October. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy